Cencora, Inc. $COR Holdings Lifted by Everhart Financial Group Inc.

Everhart Financial Group Inc. boosted its position in Cencora, Inc. (NYSE:COR) by 130.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,170 shares of the company’s stock after acquiring an additional 5,184 shares during the quarter. Everhart Financial Group Inc.’s holdings in Cencora were worth $2,753,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Deutsche Bank AG acquired a new stake in shares of Cencora in the 2nd quarter worth about $286,673,000. ExodusPoint Capital Management LP bought a new position in shares of Cencora in the fourth quarter valued at approximately $16,487,000. Impact Partnership Wealth LLC acquired a new position in shares of Cencora during the first quarter valued at approximately $1,170,000. SEB Asset Management AB acquired a new stake in Cencora in the first quarter worth approximately $134,139,000. Finally, Wedge Capital Management L L P NC increased its position in shares of Cencora by 31.0% during the 2nd quarter. Wedge Capital Management L L P NC now owns 105,614 shares of the company’s stock valued at $29,887,000 after purchasing an additional 24,968 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Trading Up 0.7%

Cencora stock traded up $2.21 during midday trading on Thursday, reaching $319.46. The stock had a trading volume of 283,955 shares, compared to its average volume of 1,479,787. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58. The firm has a market cap of $60.96 billion, a price-to-earnings ratio of 23.72, a PEG ratio of 1.62 and a beta of 0.58. The firm’s fifty day simple moving average is $318.08 and its two-hundred day simple moving average is $302.75.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.35 by $0.13. The company had revenue of $84.75 billion for the quarter, compared to the consensus estimate of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The company’s revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the business earned $4.00 EPS. Equities analysts anticipate that Cencora, Inc. will post 17.87 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Friday, August 14th were given a dividend of $0.60 per share. The ex-dividend date was Friday, August 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. Cencora’s dividend payout ratio (DPR) is presently 17.83%.

Insiders Place Their Bets

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the transaction, the executive vice president owned 19,455 shares of the company’s stock, valued at $6,305,754.60. The trade was a 36.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.38% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on COR. Evercore reaffirmed an “outperform” rating and set a $350.00 target price on shares of Cencora in a report on Thursday, August 6th. Citigroup reissued a “buy” rating on shares of Cencora in a research note on Thursday, August 6th. UBS Group lifted their price target on shares of Cencora from $412.00 to $430.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Morgan Stanley upped their price target on Cencora from $342.00 to $346.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, Bank of America increased their price objective on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a research report on Wednesday, June 24th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $372.07.

Cencora Company Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.